Skip to main content
Top
Published in: Clinical and Translational Oncology 2/2014

01-02-2014 | Research Article

What is the future burden of HPV-related cancers in Spain?

Authors: D. L. B. de Souza, M. P. Curado, M. M. Bernal, J. Jerez Roig

Published in: Clinical and Translational Oncology | Issue 2/2014

Login to get access

Abstract

Purpose

The aim of this study is to analyze mortality trends of HPV-related cancers in Spain by gender, during the period 1996–2010, and make predictions until the year 2025.

Methods

All deaths registered as cervical cancer were registered (ICD-10 code: C53), as well as vulvar and vaginal (C51 and C52), anal (C21), penile (C60), and oropharyngeal (C02, C09, C10). Adjusted rate calculations for each year were used to study the trends through the regression program Joinpoint. Predictions were made using the Nordpred program, utilizing the age–period–cohort model.

Results

In men, a statistically significant increase was observed in mortality by anal cancer, a reduction was observed in oropharyngeal cancer mortality and penile cancer rates were stable. In women, a statistically significant decreasing trend was observed for cervical, vulvar and vaginal cancers. In the predictions, the annual change relative to risk or population changes (size and structure) revealed a reduction in death risk by oropharyngeal cancer in men, and a reduction in death risk by anal cancer in women, although stable adjusted rates were verified for anal cancer in women.

Conclusions

Although an increase was identified in the number of deaths for both genders, rates indicate gender differences in the trends, with increased rates for anal cancer and reduced rates for oropharyngeal cancer in men. Women presented reduced rates for cervical, vulvar, and vaginal cancers. For penile cancer and anal cancer in women, stable trends were verified.
Literature
1.
go back to reference Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health. 2008;43(Suppl 4):52–60.CrossRef Gillison ML. Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health. 2008;43(Suppl 4):52–60.CrossRef
2.
go back to reference Oaknin A, De Diaz Corcuera I, Rodríguez-Freixinos V, Rivera F, Del Campo JM, SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for cervical cancer. Clin Transl Oncol. 2012;14:516–9.PubMedCrossRef Oaknin A, De Diaz Corcuera I, Rodríguez-Freixinos V, Rivera F, Del Campo JM, SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for cervical cancer. Clin Transl Oncol. 2012;14:516–9.PubMedCrossRef
3.
go back to reference de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.PubMedCrossRef de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.PubMedCrossRef
4.
go back to reference IARC Working Group on the evaluation of carcinogenic risks to humans. A review of carcinogen-Part B: biological agents. Lyon: IARC Publications; 2011. IARC Working Group on the evaluation of carcinogenic risks to humans. A review of carcinogen-Part B: biological agents. Lyon: IARC Publications; 2011.
5.
go back to reference Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(Suppl 4):20–6.CrossRef Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(Suppl 4):20–6.CrossRef
6.
go back to reference Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15:6758–62.PubMedCrossRef Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15:6758–62.PubMedCrossRef
7.
go back to reference de Oña M, Álvarez-Argüelles ME, Torrents M, Villa L, Rodríguez-Feijoo A, Palacio A, et al. Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol. 2010;82:597–604.PubMedCrossRef de Oña M, Álvarez-Argüelles ME, Torrents M, Villa L, Rodríguez-Feijoo A, Palacio A, et al. Prevalence, evolution, and features of infection with human papillomavirus: a 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol. 2010;82:597–604.PubMedCrossRef
8.
go back to reference García-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, et al. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. Acta Cytol. 2010;54:159–64.PubMedCrossRef García-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, et al. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. Acta Cytol. 2010;54:159–64.PubMedCrossRef
9.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Available at: http://globocan.iarc.fr. Accessed 16/06, 2013. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Available at: http://​globocan.​iarc.​fr. Accessed 16/06, 2013.
11.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.PubMedCrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.PubMedCrossRef
12.
go back to reference Moller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talback M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.PubMedCrossRef Moller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talback M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.PubMedCrossRef
13.
15.
go back to reference de Souza DL, De Camargo Cancela M, Pérez MM, Curado MP. Trends in the incidence of oral cavity and oropharyngeal cancers in Spain. Head Neck. 2012;34:649–54.PubMedCrossRef de Souza DL, De Camargo Cancela M, Pérez MM, Curado MP. Trends in the incidence of oral cavity and oropharyngeal cancers in Spain. Head Neck. 2012;34:649–54.PubMedCrossRef
17.
go back to reference Fernández E, Schiaffino A, García M, Saltó E, Villalbí JR, Borràs JM. Prevalencia de Tabaco en españa entre 1945 y 1995. Reconstrucción a partir de las Encuestas Nacionales de Salud. Med Clín (Barc). 2003;120:14–6. Fernández E, Schiaffino A, García M, Saltó E, Villalbí JR, Borràs JM. Prevalencia de Tabaco en españa entre 1945 y 1995. Reconstrucción a partir de las Encuestas Nacionales de Salud. Med Clín (Barc). 2003;120:14–6.
19.
go back to reference Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):11–25.CrossRef Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):11–25.CrossRef
20.
go back to reference Cortes J, Martinon-Torres F, Ramon y Cajal JM, Ferret G, Gil A. Considerations on the clinical application of the human papillomavirus vaccine in Spain. Hum Vaccin. 2011;7:585–9.PubMedCrossRef Cortes J, Martinon-Torres F, Ramon y Cajal JM, Ferret G, Gil A. Considerations on the clinical application of the human papillomavirus vaccine in Spain. Hum Vaccin. 2011;7:585–9.PubMedCrossRef
21.
go back to reference Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.PubMedCrossRef Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.PubMedCrossRef
22.
go back to reference De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–36.PubMedCrossRef De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–36.PubMedCrossRef
23.
go back to reference Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20:449–57.PubMedCrossRef Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20:449–57.PubMedCrossRef
24.
go back to reference Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N. The state of the art of cancer control in 30 European countries in 2008. Int J Cancer. 2010;126:2700–15.PubMed Bastos J, Peleteiro B, Gouveia J, Coleman MP, Lunet N. The state of the art of cancer control in 30 European countries in 2008. Int J Cancer. 2010;126:2700–15.PubMed
25.
go back to reference De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer. 2009;45:2632–9.PubMedCrossRef De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer. 2009;45:2632–9.PubMedCrossRef
26.
go back to reference Monsonego J, Zerat L, Syrjanen K, Zerat JC, Smith JS, Halfon P. Prevalence of type-specific human papillomavirus infection among women in France: implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Vaccine. 2012;30:5215–21.PubMedCrossRef Monsonego J, Zerat L, Syrjanen K, Zerat JC, Smith JS, Halfon P. Prevalence of type-specific human papillomavirus infection among women in France: implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Vaccine. 2012;30:5215–21.PubMedCrossRef
27.
go back to reference Limia A, Pachon I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill. 2011;16:19873.PubMed Limia A, Pachon I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill. 2011;16:19873.PubMed
28.
go back to reference Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010;46(Suppl 4):12–9.CrossRef Palefsky JM. Human papillomavirus-related disease in men: not just a women’s issue. J Adolesc Health. 2010;46(Suppl 4):12–9.CrossRef
29.
go back to reference Cortes-Bordoy J, Martinon-Torres F. The Spanish human papillomavirus vaccine consensus group: a working model. Hum Vaccin. 2010;6:635–9.PubMedCrossRef Cortes-Bordoy J, Martinon-Torres F. The Spanish human papillomavirus vaccine consensus group: a working model. Hum Vaccin. 2010;6:635–9.PubMedCrossRef
30.
go back to reference Ministerio de Sanidad y Consumo. Estrategias en cáncer del sistema nacional de salud. Madrid: Ministerio de Sanidad y Consumo-Centro de Publicaciones; 2006. Ministerio de Sanidad y Consumo. Estrategias en cáncer del sistema nacional de salud. Madrid: Ministerio de Sanidad y Consumo-Centro de Publicaciones; 2006.
Metadata
Title
What is the future burden of HPV-related cancers in Spain?
Authors
D. L. B. de Souza
M. P. Curado
M. M. Bernal
J. Jerez Roig
Publication date
01-02-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 2/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1064-7

Other articles of this Issue 2/2014

Clinical and Translational Oncology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine